CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 134 filers reported holding CYMABAY THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 1.59 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,084,580 | +100.6% | 273,949 | +78.7% | 0.14% | +25.2% |
| Q1 2019 | $2,036,000 | +338.8% | 153,298 | +265.8% | 0.12% | +259.4% |
| Q3 2018 | $464,000 | -68.5% | 41,912 | -61.9% | 0.03% | -57.9% |
| Q2 2018 | $1,475,000 | -75.1% | 109,934 | -75.9% | 0.08% | -69.8% |
| Q1 2018 | $5,918,000 | +15.1% | 455,600 | -18.5% | 0.25% | -6.7% |
| Q4 2017 | $5,143,000 | +19.7% | 559,000 | +4.9% | 0.27% | +24.4% |
| Q3 2017 | $4,296,000 | -5.4% | 533,000 | -32.4% | 0.22% | -11.8% |
| Q2 2017 | $4,540,000 | +45.4% | 788,125 | +8.6% | 0.25% | +59.7% |
| Q1 2017 | $3,122,000 | +446.8% | 726,000 | +119.9% | 0.15% | +305.3% |
| Q4 2016 | $571,000 | +76.8% | 330,207 | +38.0% | 0.04% | +90.0% |
| Q1 2016 | $323,000 | -46.3% | 239,260 | -32.8% | 0.02% | -67.7% |
| Q4 2015 | $602,000 | -13.6% | 356,260 | -0.9% | 0.06% | +3.3% |
| Q3 2015 | $697,000 | – | 359,500 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 2,023,369 | $27,154,000 | 9.26% |
| Omega Fund Management, LLC | 551,477 | $7,401,000 | 5.46% |
| Foresite Capital Management III, LLC | 1,562,040 | $20,963,000 | 4.51% |
| Versant Venture Management, LLC | 1,048,601 | $14,072,225,000 | 4.39% |
| Boxer Capital, LLC | 2,094,000 | $28,101,000 | 3.18% |
| Opaleye Management Inc. | 697,500 | $9,360,000 | 2.42% |
| Abingworth LLP | 273,417 | $3,667,000 | 2.10% |
| DAFNA Capital Management LLC | 294,511 | $3,952,000 | 1.85% |
| NEXTHERA CAPITAL LP | 828,655 | $11,121,000 | 1.72% |
| Vivo Capital, LLC | 906,000 | $12,158,000 | 1.57% |